Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience.
Letermovir
allogeneic stem cell transplantation
cytomegalovirus infection
prophylaxis
real-world data
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
07
2021
accepted:
13
08
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
8
10
2021
Statut:
epublish
Résumé
Despite effective treatments, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. This multicenter, retrospective, cohort study aimed to evaluate the reproducibility of the safety and efficacy of commercially available letermovir for CMV prophylaxis in a real-world setting. Endpoints were rates of clinically significant CMV infection (CSCI), defined as CMV disease or CMV viremia reactivation within day +100-+168. 204 adult CMV-seropositive allo-SCT recipients from 17 Italian centres (median age 52 years) were treated with LET 240 mg/day between day 0 and day +28. Overall, 28.9% of patients underwent a haploidentical, 32.4% a matched related, and 27.5% a matched unrelated donor (MUD) transplant. 65.7% were considered at high risk of CSCI and 65.2% had a CMV seropositive donor. Low to mild severe adverse events were observed in 40.7% of patients during treatment [gastrointestinal toxicity (36.3%) and skin rash (10.3%)]. Cumulative incidence of CSCI at day +100 and day +168 was 5.4% and 18.1%, respectively, whereas the Kaplan-Meier event rate was 5.8% (95% CI: 2.4-9.1) and 23.3% (95% CI: 16.3-29.7), respectively. Overall mortality was 6.4% at day +100 and 7.3% at day +168. This real-world experience confirms the efficacy and safety of CMV.
Identifiants
pubmed: 34616684
doi: 10.3389/fonc.2021.740079
pmc: PMC8489185
doi:
Types de publication
Journal Article
Langues
eng
Pagination
740079Informations de copyright
Copyright © 2021 Martino, Pitino, Gori, Bruno, Crescimanno, Federico, Picardi, Tringali, Ingrosso, Carluccio, Pastore, Musuraca, Paviglianiti, Vacca, Serio, Storti, Mordini, Leotta, Cimminiello, Prezioso, Loteta, Ferreri, Colasante, Merla, Giaccone, Busca, Musso, Scalone, Di Renzo, Marotta, Mazza, Musto, Attolico, Selleri, Canale, Pugliese, Tripepi, Porto, Martinelli, Carella and Cerchione.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.
Références
Biol Blood Marrow Transplant. 2018 Oct;24(10):2101-2109
pubmed: 29777868
Blood. 2016 May 19;127(20):2427-38
pubmed: 26884374
Diagn Microbiol Infect Dis. 2019 Oct;95(2):152-158
pubmed: 31204110
Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381
pubmed: 30292744
Expert Rev Hematol. 2019 Nov;12(11):937-945
pubmed: 31423858
Ophthalmology. 2012 Sep;119(9):1892-8
pubmed: 22657564
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Bone Marrow Transplant. 1994 Jun;13(6):783-8
pubmed: 7920315
Adv Ther. 2018 Nov;35(11):1763-1774
pubmed: 30357570
Clin Infect Dis. 2003 Mar 15;36(6):749-58
pubmed: 12627359
J Antimicrob Chemother. 2001 Dec;48(6):757-67
pubmed: 11733458
J Clin Oncol. 2009 Feb 10;27(5):770-81
pubmed: 19114702
N Engl J Med. 2017 Dec 21;377(25):2433-2444
pubmed: 29211658
Bone Marrow Transplant. 2000 Jul;26(1):23-9
pubmed: 10918402
Blood Adv. 2018 Aug 28;2(16):2159-2175
pubmed: 30154125
Expert Rev Hematol. 2016 Jun;9(6):585-96
pubmed: 27043241
Future Microbiol. 2017 Aug;12:839-842
pubmed: 28745073
Am J Transplant. 2021 Apr;21(4):1622-1628
pubmed: 33320429
Infect Drug Resist. 2019 May 08;12:1127-1138
pubmed: 31190905
Blood. 2002 Apr 15;99(8):3050-6
pubmed: 11929799
J Med Econ. 2020 Dec;23(12):1485-1492
pubmed: 33155494
Lancet Infect Dis. 2011 Apr;11(4):284-92
pubmed: 21414843
Antiviral Res. 2001 Mar;49(3):179-89
pubmed: 11428244
Blood. 1996 Nov 15;88(10):4063-71
pubmed: 8916975
Ann Hematol. 2021 Aug;100(8):2087-2093
pubmed: 33270162
Clin Infect Dis. 2020 Apr 10;70(8):1525-1533
pubmed: 31179485
Ann Intern Med. 1993 Feb 1;118(3):173-8
pubmed: 8380242
Clin Infect Dis. 2002 Apr 15;34(8):1094-7
pubmed: 11914998
Clin Transplant. 2019 Oct;33(10):e13666
pubmed: 31310687
Ann Intern Med. 1993 Feb 1;118(3):179-84
pubmed: 8380243
Blood. 2004 Mar 15;103(6):2003-8
pubmed: 14644993
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151230
Lancet Infect Dis. 2019 Aug;19(8):e260-e272
pubmed: 31153807
Lancet. 1994 Mar 26;343(8900):749-53
pubmed: 7907729
Front Cell Dev Biol. 2020 Oct 27;8:534268
pubmed: 33195184
Blood. 2013 Nov 7;122(19):3359-64
pubmed: 24037724
Lancet Haematol. 2016 Mar;3(3):e119-27
pubmed: 26947200
Haematologica. 2014 May;99(5):908-15
pubmed: 24488562